Free Trial

Genmab A/S Q2 2023 Earnings Report

Genmab A/S logo
$209.50 +2.15 (+1.04%)
(As of 12/20/2024 05:55 PM ET)

Genmab A/S EPS Results

Actual EPS
$3.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genmab A/S Revenue Results

Actual Revenue
$613.43 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genmab A/S Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

Genmab A/S Earnings Headlines

TD Cowen Reaffirms Their Hold Rating on Genmab (GMAB)
Genmab A/S: Circling Back On This Complicated Story
DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Genmab A/S Expands Share Capital and Warrants
Genmab Discloses Share Transactions by Executives
See More Genmab A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email.

About Genmab A/S

Genmab A/S (OTCMKTS:GNMSF) develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

View Genmab A/S Profile

More Earnings Resources from MarketBeat

Upcoming Earnings